Back to School: How biopharma can reboot drug development. Access exclusive analysis here

0821 ECP Luminary
BioCentury & Getty Images

Emerging Company Profile

Luminary: turning cell engineering tools into therapies

Former B-MoGen execs leverage experience in non-viral cell engineering tools to form therapeutic start-up

Luminary’s founders are taking advantage of their experience in developing non-viral genome engineering tools to develop engineered cell therapies. 

Aug 22, 2020 | 2:16 AM GMT

Luminary is parlaying its founders’ experience in non-viral genome engineering to build a pipeline of cell therapies that are faster to develop and more cost-effective than those that depend on virus-based technologies.

Luminary Therapeutics Inc. was carved out

Read the full 883 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers